| Roland G Nador, MD | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 498-5710 | |
| Not Available |
| Full Name | Roland G Nador |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639118508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A75896 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Roland G Nador, MD 2680 Hanover St, Palo Alto, CA 94304-1117 Ph: () - | Roland G Nador, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 498-5710 |
News Archive
DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.
The REal-time Assessment of Community Transmission-2 (REACT-2) program completed its fifth round of community surveys in the days between January 26 and February 8, 2021. The findings appear in a new article in the BMJ on February 25, 2021, showing that natural infection and vaccination together account for around 14% seropositivity rates in England at present.
Advanced Cell Technology, Inc. announced today that human embryonic stem cell line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director National Institutes of Health. In addition to MA135, seven additional stem cell lines derived at ACT are currently under review by the NIH.
Pompe disease is a hereditary genetic disorder caused by a deficiency of acid alpha-glucosidase leading to build-up of glycogen in the lyosomes, which then causes cell damage in various tissues, in particular the heart, the muscles, the liver and the nervous system.
› Verified 7 days ago
Prista Charuworn, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Alway Build M211, Mc 5187, Stanford, CA 94305 Phone: 650-723-6661 | |
Dr. Yu Kuang Lai, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Andrea Lorenze, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Drive, Lane 154, Stanford, CA 94305 Phone: 650-723-6661 Fax: 650-498-6205 | |
Audra Horomanski, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 Fax: 650-498-6205 | |
Dr. Meghan Brady Marmor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, H3143, Stanford, CA 94305 Phone: 650-723-1150 Fax: 650-725-5489 | |
Lauren Michelle Ulsh, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Ann M Chen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, A149, Mc5202, Stanford, CA 94305 Phone: 650-725-3376 Fax: 650-723-8305 |